Ftse Mib
33.682,10
-0,45%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
62.128,35
3,10%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Applied Therapeutics Inc (APLT) Applied Therapeutics Inc (APLT) Notizie

APLT

Applied Therapeutics (APLT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLT
DataOraFonteTitoloSimboloCompagnia
10/06/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLTApplied Therapeutics Inc
06/06/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLTApplied Therapeutics Inc
05/06/202422:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/05/202413:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLTApplied Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.Applied Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
07/05/202413:00GlobeNewswire Inc.Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:APLTApplied Therapeutics Inc
15/04/202413:00GlobeNewswire Inc.Applied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerNASDAQ:APLTApplied Therapeutics Inc
04/04/202413:00GlobeNewswire Inc.Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024NASDAQ:APLTApplied Therapeutics Inc
28/03/202421:30GlobeNewswire Inc.Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
06/03/202413:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLTApplied Therapeutics Inc
06/03/202413:00GlobeNewswire Inc.Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
05/03/202423:42Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:APLTApplied Therapeutics Inc
28/02/202414:05GlobeNewswire Inc.Applied Therapeutics Announces $100 Million Private PlacementNASDAQ:APLTApplied Therapeutics Inc
28/02/202414:00GlobeNewswire Inc.Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
22/02/202420:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLTApplied Therapeutics Inc
15/02/202413:00GlobeNewswire Inc.Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) DeficiencyNASDAQ:APLTApplied Therapeutics Inc
13/02/202422:34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLTApplied Therapeutics Inc
04/01/202422:05GlobeNewswire Inc.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyNASDAQ:APLTApplied Therapeutics Inc
03/01/202417:20Dow Jones NewsApplied Therapeutics Shares Hit 52-Week High on Govorestat FilingsNASDAQ:APLTApplied Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
09/11/202313:30GlobeNewswire Inc.Applied Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
02/11/202312:00GlobeNewswire Inc.Applied Therapeutics to Present at the UBS Biopharma Conference 2023NASDAQ:APLTApplied Therapeutics Inc
01/11/202312:00GlobeNewswire Inc.Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7NASDAQ:APLTApplied Therapeutics Inc
28/09/202313:00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingNASDAQ:APLTApplied Therapeutics Inc
06/09/202317:08Dow Jones NewsApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDANASDAQ:APLTApplied Therapeutics Inc
06/09/202313:00GlobeNewswire Inc.Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023NASDAQ:APLTApplied Therapeutics Inc
11/08/202322:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLTApplied Therapeutics Inc
10/08/202313:00GlobeNewswire Inc.Applied Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
25/07/202313:00GlobeNewswire Inc.Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNASDAQ:APLTApplied Therapeutics Inc
23/06/202322:41Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APLTApplied Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLT

La tua Cronologia

BOV
APXM11
Units
BIT
NSCIT2712544
European Bank for Recons...
USOTC
KOSK
Metawells Oil and Gas (PK)
EU
BE0002657386
Gimv NV 2.875% 5jul2026
BIT
S29681
Societe Generale Effekten
LSE
RF46
Mort.bt 22-1.54
COIN
LADYSUSD
Milady
NYSE
SQ
Block
NYSE
TKO
Tko
UNSW3
PHTRETH
Phuture
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network